Amantadine extended release - Osmotica Pharmaceutical

Drug Profile

Amantadine extended release - Osmotica Pharmaceutical

Alternative Names: ALLAY-LID I; ALLAY-LID II; Amantadine HCl ER; Amantadine HCl Extended Release Tablets - Osmotica Pharmaceutical; OS-320; Osmolex ER

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Osmotica Pharmaceutical
  • Class Adamantanes; Antiparkinsonians; Antivirals; Organic bridged compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists; Dopamine release stimulants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity No

Highest Development Phases

  • Registered Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

  • 19 Feb 2018 Registered for Drug-induced dyskinesia in USA (PO)
  • 19 Feb 2018 Registered for Parkinson's disease in USA (PO)
  • 22 Jul 2015 Amantadine extended release - Osmotica Pharmaceutical receives Orphan Drug status for Drug-induced dyskinesia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top